Background: As reported, preclinical animal models differ greatly from the human body. The evaluation model may be the colossal obstacle for scientific research and anticancer drug development. Therefore, it is essential to propose efficient evaluation systems similar to clinical practice for cancer research.
Main body: While it has emerged for decades, the development of patient-derived xenografts, patient-derived organoid and patient-derived cell used to be limited. As the requirements for anticancer drug evaluation increases, patient-derived models developed rapidly recently, which is widely applied in basic research, drug development, and clinical application and achieved remarkable progress. However, there still lack systematic comparison and summarize reports for patient-derived models. In the current review, the development, applications, strengths, and challenges of patient-derived models in cancer research were characterized.
Conclusion: Patient-derived models are an indispensable approach for cancer research and human health.
Keywords: NCI-60; Patient-derived cell (PDC); Patient-derived model; Patient-derived organoid (PDO); Patient-derived xenograft (PDX).
© 2022. The Author(s).